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Abstract
There is convincing evidence that consumption of fish and fish oil rich in long-chain (LC) n-3 PUFA (n-3 LCPUFA), EPA (20 : 5n-3) and DHA
(22 : 6n-3) reduce the risk of CHD. The aim of the present study was to investigate whether n-3 LCPUFA-enriched food products provide
similar beneficial effects as fish oil with regard to incorporation into plasma lipids and effects on cardiovascular risk markers. A parallel
7-week intervention trial was performed where 159 healthy men and women were randomised to consume either 34 g fish paˆte´ (n 44),
500 ml fruit juice (n 38) or three capsules of concentrated fish oil (n 40), all contributing to a daily intake of approximately 1 g EPA
and DHA. A fourth group did not receive any supplementation or food product and served as controls (n 37). Plasma fatty acid compo-
sition, serum lipids, and markers of inflammation and oxidative stress were measured. Compared with the control group, plasma n-3
LCPUFA and EPA:arachidonic acid ratio increased equally in all intervention groups. However, no significant changes in blood lipids
and markers of inflammation and oxidative stress were observed. In conclusion, enriched fish paˆte´ and fruit juice represent suitable deliv-
ery systems for n-3 LCPUFA. However, although the dose given is known to reduce the risk of CVD, no significant changes were observed
on cardiovascular risk markers in this healthy population.
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The health benefits of long-chain (LC) n-3 PUFA (n-3 LCPUFA)
of marine origin, in particular EPA (20 : 5n-3) and DHA
(22 : 6n-3), are well documented, indicating protective
effects on CVD, autoimmune and mental disorders(1–5). n-3
LCPUFA appear to reduce the risk of CVD through a wide
range of beneficial effects, including anti-atherothrombogenic
effect and reduction in serum TAG, whereas there are some
inconsistencies regarding the effects on arrhythmia, hypertension
and inflammation(6–17). However, n-3 LCPUFA are prone to
oxidation, which may lead to increased susceptibility to oxi-
dation and atherogenicity of LDL-cholesterol, and increased
risk of CVD(18–20). High levels of F2-isoprostanes, formed
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from the free radical-induced peroxidation of membrane-
bound arachidonic acid (AA, 20 : 4n-6), have been associated
with higher cardiovascular risk(21–24). Still, the role of n-3
LCPUFA in oxidative stress is unclear.
In the literature, recommended daily intakes of n-3 LCPUFA
vary from 200 mg to 1 g EPA and DHA(25). Recent evidence
shows that the intake of EPA and DHA is inversely related to
cardiovascular risk in a dose-dependent manner up to about
250 mg/d in healthy populations, and intake of 1 g/d is associ-
ated with a marked protection from sudden cardiac
death(2,6,26,27). A growing market for n-3 LCPUFA-fortified
foods may provide recommended amounts for people
whose diet is inadequate. However, whether consumption of
such products provides the same health benefits as fish con-
sumption or fish oil supplementation has to be established.
There is an ongoing discussion about the preferred ‘delivery
system’ for n-3 fatty acids, i.e. food v. supplement, with
respect to bioavailability and physiological function. The mol-
ecular form of the lipids, the food matrix and possible inter-
actions with other food components may have an impact on
the absorption and incorporation of EPA and DHA into
plasma lipids. Some studies have indicated that fish consump-
tion is more effective in increasing serum concentrations of
n-3 LCPUFA than fish oil(28,29), whereas others have shown
almost identical increases when comparing equal intakes of
EPA and DHA from fish and capsules(30). In a single-meal
study, fish oil incorporated into food products was absorbed
differently from the same fish oil in capsules, and the rate
of absorption varied depending on the food matrix(31).
Both level and type of emulsifiers and phospholipids in
foods may influence lipid bioavailability(32); still, it is
unclear whether steady-state levels of plasma EPA and DHA,
obtained after regular daily intake, are also influenced by
the food matrix.
In a previous intervention study, intake of fish paˆte´ enriched
in EPA and DHA indicated efficient incorporation into blood
lipids and favourable effects on inflammatory markers(33).
In the present study, the same fish paˆte´ and n-3 LCPUFA-
enriched fruit juice were compared with fish oil with regard
to incorporation into plasma lipids and effects on cardiovascu-
lar risk markers, e.g. serum lipids, plasma fatty acid profile,
and markers of inflammation and oxidative stress. The aim
was to investigate whether n-3 LCPUFA-enriched food pro-
ducts provide similar beneficial effects as fish oil when con-
suming 1 g/d EPA and DHA, a recommended intake known
to reduce the risk of CVD.
Experimental methods
Participants
Participants were recruited by local advertising in the commu-
nity of Akershus, Norway. Men and women, aged 18–70
years, with normal to slightly increased cholesterol and TAG
levels (total cholesterol ,7·5 mmol/l and TAG ,4·0 mmol/l)
and C-reactive protein (,10 mg/l) were included. Exclusion
criteria were regular fatty fish consumption (.1/week of
salmon, trout, herring, sardine and mackerel), diagnosis of
familial hypercholesterolaemia, secondary hyperlipidaemia,
chronic rheumatoid disease, coronary, peripheral or cerebro-
vascular disease within the previous 3 months of inclusion,
BMI $30 kg/m2, hypertension ($160/100 mmHg), use of
medication to lower serum lipids, blood pressure and inflam-
mation, pregnancy and lactation. Subjects who used n-3
LCPUFA supplements regularly were asked to terminate the
use of supplements 2 months before inclusion (n 19). The 2
months washout period was considered appropriate based
on the reduced level of EPA and DHA in serum cholesteryl
esters reported previously during washout after n-3 sup-
plementation(34). The study was conducted according to the
guidelines in the Declaration of Helsinki and approved by
the regional Ethics Committee. Written informed consent
was obtained from all participants. A validated FFQ(35) was
used in order to check the background diet of the subjects.
All subjects, including the control group, were instructed by
a nutritionist not to change their habitual diet (including
changes in fatty fish intake and use of n-3 supplements), to
keep a stable weight and not to change their lifestyle during
the intervention period. The intervention period did not
include summer or Christmas holidays.
Study design
The study was part of a larger study, which has been
published previously(36). It was a single-centre intervention
study with an open, randomised, parallel-group design con-
ducted at the Akershus University College, Kjeller, Norway.
Intervention products to be tested were n-3 LCPUFA-enriched
fish paˆte´, n-3 LCPUFA-enriched fruit juice and concentrated
fish oil in capsules. In total, 369 phone calls were received
and 207 subjects were invited to a screening visit (visit 1). Sub-
jects eating fatty fish regularly more than once per week were
excluded at the phone interviews. Screening of subjects
(n 199) was performed within 3 weeks before inclusion in
order to identify subjects who satisfied the eligibility criteria
(n 179). The evaluation conducted at screening included
assessment of C-reactive protein and serum lipids. Demo-
graphic information (age, sex and ethnicity), concomitant
medication and medical history were registered, and a brief
physical examination (weight, height and blood pressure)
was conducted. Subjects who satisfied the eligibility criteria
(n 179) were randomised into four study groups. Before the
baseline visit (visit 2), nine subjects were lost, whereas
eleven subjects dropped out during the study period. In the
n-3 LCPUFA-enriched fruit juice group, two subjects did not
manage to consume the product, in the n-3 LCPUFA-enriched
fish paˆte´ group there were five dropouts (two did not manage
to eat the product, two got clinical symptoms such as stomach
pain and nausea and one was lost to follow-up) and in the
control group four subjects were lost to follow-up. A total of
159 subjects finished the study, and they had consumed
either 500 ml n-3 LCPUFA-enriched fruit juice (n 38), 34 g
n-3 LCPUFA-enriched fish paˆte´ (n 44) or three capsules of
fish oil (n 40) daily for 7 weeks in order to obtain an intake
of approximately 1 g/d EPA and DHA (Table 1). A control
group that did not receive any products (n 37) was included

















to account for seasonal variation. The participants were
advised to include fish paˆte´ and fruit juice in meals where
they commonly used bread or a beverage and the capsules to
be consumed at breakfast or other regular meals. All products
were delivered free of charge. At the end of the 7-week inter-
vention period, the subjects met for a final visit (visit 3). Blood
and urine samples were collected at visits 2 and 3 for assess-
ments of efficacy. A change in concomitant medication and
smoking habits from baseline and clinical symptoms during
the intervention period were registered in the case report
form at each visit. In total, eighteen subjects were using a
stable dose of hormonal contraceptives before and during
the study, and eight subjects were using drugs against aller-
gies. The number of subjects taking medication was equally
distributed among the study groups. The total number of
smokers was eighteen. The number of cigarettes per d
varied among the subjects (from 1 up to 20 per d), but the
number was stable for each subject before and during the
study. Compliance was ensured through regular telephone
contact with the participants and monitored by collecting
leftover study products and empty containers at visit 3. Com-
pliance was satisfactory in all groups; 94 % in the fish paˆte´
group, 100 % in the juice group and 100 % in the fish oil group.
Products
Fish paˆte´ was based on a commercial product manufactured
by Mills DA, Oslo, Norway. The main ingredients were
farmed Atlantic salmon (Salmo salar), rapeseed oil, water
and fish oil (refined cod-liver oil; Denomega Nutritional
Oils, Sarpsborg, Norway). Fish oil was added to increase the
contents of DHA and EPA to about twice the natural content.
The product was gently processed under carefully controlled
conditions, high-temperature pasteurised and packed in Al
tubes. Fruit juice was based on concentrates of fruits and ber-
ries, with no sugar added. It was developed and delivered
by Mills DA, in collaboration with Ska˚nemejerier, Malmø,
Sweden, where it was produced by adding fish oil (refined
cod-liver oil; Denomega Nutritional Oils) through a patented
technique (patent no. Norge 325446, ‘Lipid composition and
use thereof’). Fish oil capsules (Peter Møllers Dobbel, Axellus,
Norway) were a commercial food supplement of concentrated
fish oil (TAG). The capsules were made of gelatine softened
with glycerol. All intervention products were obtained from
large-scale production and subjected to regular in-house
quality tests, including routine sensory analysis and analysis
of peroxide value. Sensory analysis was performed by a
panel consisting of company employees specially trained to
detect oxidative attributes such as rancidity. The participants
were told to keep the food products refrigerated in order to
ensure oxidative stability throughout the shelf-life period.
Fish oil capsules were stored at room temperature. The fatty
acid composition of the study products is presented in
Table 1. Fatty acid content was analysed by The Norwegian
Institute for Food and Environmental Analysis Inc. (Oslo,
Norway) using a modified Caviezel method(37). Lipids were
extracted using a modified Bligh & Dyer method(38). Fatty
acid concentrations were determined by GLC of fatty acid
methyl esters on a fused-silica wall-coated capillary column
(Chrompack CP-Wax-52 CB, 25 mm £ 0·25 mm) in a Perkin-
Elmer Auto System XL (Perkin Elmer Inc., Waltham, MA, USA).
Blood sampling
Blood from venepuncture was collected after an overnight fast
($12 h). Subjects were instructed to refrain from alcohol con-
sumption and from vigorous physical activity the day before
the blood sampling. Serum was obtained from silica gel
tubes (BD Vacutainer, Plymouth, Devon, UK), kept at room
temperature for at least 30 min until centrifugation at 1300 g
for 12 min. Plasma was obtained from EDTA tubes (BD Vacu-
tainer) kept on ice and centrifuged at 1300 g for 10 min at 108C
within 2 h. Samples were kept frozen (2808C) until analysis.
Table 1. Fatty acid composition of the study products (percentage of fatty acids)
Fruit juice (500 ml) Fish paˆte´ (34 g) Fish oil (three capsules)
Fatty acids % Daily dose (g) % Daily dose (g) % Daily dose (g)
14 : 0 1·8 0·09 1·9 0·18 3·2 0·05
16 : 0 14·0 0·65 8·75 0·80 7·8 0·13
18 : 0 4·3 2·05 3·7 0·33 2·6 0·04
16 : 1n-7 3·2 0·15 2·8 0·25 3·9 0·07
18 : 1n-7 3·4 0·16 3·75 0·34 2·2 0·04
18 : 1n-9 26·0 1·25 36·5 3·28 6·1 0·10
20 : 1n-9 1·6 0·08 3·05 0·27 2·0 0·03
22 : 1n-11 1·4 0·07 1·9 0·17 2·5 0·04
18 : 2n-6 19·0 0·90 12·0 1·11 0·8 0·01
18 : 3n-3 1·3 0·06 5·1 0·46 0·5 0·01
18 : 4n-3 0·9 0·05 0·75 0·07 1·9 0·03
20 : 4n-6 (AA) 0·6 0·03 0·25 0·04 1·5 0·03
20 : 5n-3 (EPA) 8·7 0·41 6·65 0·60 27·0 0·45
22 : 5n-3 (DPA) 1·5 0·07 1·65 0·15 4·8 0·08
22 : 6n-3 (DHA) 7·6 0·35 5·95 0·54 24·0 0·41
EPAþDHA 16·3 0·8 12·6 1·1 51·0 0·9
Total fat 5·0 9·6 1·8
AA, arachidonic acid; DPA, docosapentaenoic acid.

















Serum lipids and apolipoproteins
Analyses of serum total-, LDL- and HDL-cholesterol, TAG,
apoA1, and apoB were performed at the routine laboratory
at the Department of Medical Biochemistry at Oslo University
Hospital, Rikshospitalet, Oslo, Norway (ISO 17 025 accre-
dited), using standard methods (Modular System; Roche, Man-
nheim, Germany).
Plasma fatty acid composition and vitamin E
(a-tocopherol)
Plasma fatty acid composition was analysed by Jurilab Limited,
Kuopio, Finland, which used a slight modification of the
method described by Nyyssonen et al.(39). Plasma (250ml)
fatty acids and 25ml of an internal standard (eicosane 1mg/ml
in isopropanol) were extracted with 6 ml of methanol–
chloroform (1:2) and 1·5 ml of water were added. The two
phases were separated by centrifugation and the upper
phase was discarded. To the chloroform phase, 1 ml of metha-
nol–water (1:1) was added, and this extraction was repeated
twice. The chloroform phase was evaporated under N2. For
methylation, the remainder was treated with 1·5 ml of sulphu-
ric acid–methanol (1:50) at 858C for 2 h. The mixture was
diluted with 1·5 ml of water and extracted with light petroleum
diethyl ether. The fatty acids from the diethyl ether phase were
determined using a 6890 GC with an HP-5MS capillary column
and interfaced with a 5973 mass selective detector with elec-
tron impact ionisation (Agilent Technologies, Palo Alto, CA,
USA). For retention time and quantitative standardisation,
fatty acids purchased from Nu-Chek-Prep (Elysian, MN, USA)
were used.
Plasma a-tocopherol was analysed by Vitas AS, Oslo,
Norway. Briefly, 100ml of human plasma were diluted with
300ml 2-propanol containing the internal standard tocol and
butylated hydroxytoluene (BHT) as an antioxidant. After
thorough mixing (15 min) and centrifugation (10 min, 4000g
at 108C), an aliquot of 1ml was injected from the supernatant
into the HPLC system. HPLC was performed with an HP 1100
liquid chromatograph (Agilent Technologies) with an HP1100
fluorescence detector, an emission wavelength of 295 nm and
an excitation wavelength of 330 nm. Tocopherol isomers were
separated on a 2·1 mm £ 250 mm reversed phase column. The
column temperature was 408C. A two-point calibration curve
was made from an analysis of a 3 % albumin solution enriched
with a known concentration of tocopherols. Recovery is
.95 %, the method is linear from at least 1 to 200mM and
the limit of detection is 0·01mM.
Circulating inflammatory markers
Analysis of serum high-sensitivity C-reactive protein was per-
formed at the routine laboratory at the Department of Medical
Biochemistry at Rikshospitalet (ISO17025 accredited), using
a standard method (Modular System; Roche). Plasma IL-6,
TNFa, monocyte chemotactic protein-1, interferon-g, soluble
E-selectin and P-selectin, soluble intracellular adhesion
molecule-1 and vascular cell adhesion molecule-1 were
determined by Fluorokinew MAP kits from R&D Systems,
Inc. (Minneapolis, MN, USA). Plasma leukotriene B4 was ana-
lysed as described previously(29). Due to low sensitivity by the
multiplex method, IL-6 and TNFa were measured using ELISA
(R&D Systems).
Urinary F2 isoprostanes
Spot morning urine samples were analysed for 8-iso-PGF2a
by a highly specific and validated RIA as described by
Basu(40). The cross-reactivity of the 8-iso-PGF2a antibody
with 15-keto-13,14-dihydro-8-iso-PGF2a, 8-iso-PGF2b, PGF2a,
15-keto-PGF2a, 15-keto-13,14-dihydro-PGF2a, thromboxane
B-2, 11b-PGF2a, 9b-PGF2a and 8-iso-PGF3a, respectively, was
1·7, 9·8, 1·1, 0·01, 0·01, 0·1, 0·03, 1·8 and 0·6 %. The detection
limit of the assay was 23 pmol/l. Glomerular filtration rate was
assessed as equal to the clearance of creatinine and the urinary
levels of 8-iso-PGF2a were adjusted according to creatinine
concentration.
Statistical methods
Statistical analyses were performed by LINK Medical Research
AS (Oslo, Norway), an independent clinical research organis-
ation contracted for partaking in the conduct of the project.
Analyses were performed using SASw for Windows (version
9.1; SAS Institute Inc., Cary, NC, USA). The nominal level for
significance was 5 %. The power calculation was based on
observed variations in TAG in a previous parallel study(33).
Sample size calculations based on testing a null hypothesis
of no difference, using a power of 0·80 and a significance
level of 0·05, resulted in the need of including at least forty
participants in each group (SASw Power and Sample Size).
This sample size was derived by using an estimated standard
deviation of change from baseline of 0·485 mmol/l, and an
assumed expected mean change of 0·30 mmol/l in all groups
except the control group that was assumed to have a
difference of zero. Due to the potential of participants drop-
ping out of the study, it was decided to include fifty subjects
per treatment. The participants were recruited during a
period of 1 year. Due to a lower dropout rate than expected,
only 179 subjects were recruited. Continuously distributed
parameters were analysed by ANOVA. Box plots were
checked for deviations between the groups that could severely
affect the estimated P values. However, none was found.
Whenever the ANOVA test resulted in rejecting the null
hypothesis of no difference between the groups, the Scheffe´
multiple-comparison procedure based on CI was used(41).
Within-group changes from baseline to the end of intervention
were tested by paired Students t tests. All values are presented
as means and standard deviations, unless otherwise stated. In
order to detect potential associations between incorporation
of DHA and EPA into plasma lipids, the plasma EPA:AA ratio
and changes in cardiovascular risk markers, principal com-
ponent analysis and cross-correlations were performed using
Unscramblerw version 9.8 (Camo Inc., Oslo, Norway).


















Overall, 179 subjects were randomised into four groups, and
159 completed the study in accordance with the descriptions
given in the protocol. Baseline demographics and clinical
characteristics of the study groups are given in Table 2. No
differences were observed between the groups. There were
no changes in BMI and blood pressure during the intervention
period.
Plasma fatty acid profile and serum lipids
Significant differences in change from baseline between the
groups were seen for EPA, docosapentaenoic acid (22 : 5n-3),
DHA and the EPA:AA ratio, demonstrating that the control
group had a significantly (P,0·05) smaller change than the
three intervention groups (Table 3). Also, significant within-
group increases in plasma levels of EPA, docosapentaenoic
acid and DHA, and decreased levels of AA were seen in all
intervention groups, and the EPA:AA ratio increased markedly
(Table 3). EPA increased with 113, 144 and 145 %, respectively,
in the fruit juice, fish paˆte´ and fish oil capsule groups. The
increases in DHA were somewhat lower, 31, 38 and 50 %,
whereas AA decreased with 9, 2 and 7 %, respectively, in the
fruit juice, fish paˆte´ and fish oil capsule groups. Also, com-
pared with the control group, the increases in EPA, docosa-
pentaenoic acid and DHA were statistically significant, but
pairwise comparisons between the three intervention groups
gave no significant results. However, the lowest increase in
EPA and DHA was observed in the fruit juice group that had
the lowest intake (Table 1). There were only minor changes
in other plasma fatty acids (Table 3).
The changes seen in the levels of total cholesterol, HDL-
cholesterol, LDL-cholesterol and TAG were limited (Table 4).
There was a trend showing an increase in HDL (5–7 %) in
the fruit juice, fish paˆte´ and fish oil capsule groups
(P¼0·06–0·07). This was in accordance with an observed
increase in apoA (P¼0·01–0·06; Table 3). Although a few
within-group changes were statistically significant, no statisti-
cally significant differences in changes between the groups
were observed.
Inflammatory markers
There were no significant changes in the serum inflammatory
markers high-sensitivity C-reactive protein, IL-6, TNFa, leuko-
triene B4, monocyte chemotactic protein-1, intracellular
adhesion molecule-1, vascular cell adhesion molecule-1,
E-selectin and P-selectin (Table 5). A significant within-
group increase was observed for interferon-g in the fruit
juice, fish paˆte´ and fish oil capsule groups, but there were
no significant differences between the groups (Table 5).
Markers for oxidative stress
No significant changes in the urine levels of F2-isoprostane
between the study groups were observed (Table 6). The
plasma level of vitamin E (a-tocopherol) decreased in all
groups, including the control group. When calculated in
relation to the level of serum TAG, the decrease was statisti-
cally significant only in the fish paˆte´ group (Table 6). No sig-
nificant changes in the plasma levels of a-tocopherol were
observed between the groups.
Principal component analysis and cross-correlation
Principal component analysis and cross-correlations revealed
no convincing associations between incorporation of DHA
and EPA into plasma lipids and markers of inflammation
and oxidative stress, or between the plasma EPA:AA ratio
and markers of inflammation and oxidative stress (data not
shown).
Discussion
The present randomised, parallel designed intervention study
showed that intake of n-3 LCPUFA in the form of TAG from
fortified foods and concentrated fish oil capsules contributed
equally to significant increases in plasma concentrations of
EPA and DHA. Still, no significant effects were observed in
parameters associated with CVD such as serum lipids and
markers of inflammation or oxidative stress.
Table 2. Baseline characteristics and plasma lipids
(Mean values and standard deviations)
Fish paˆte´ Fruit juice Fish oil capsules Control
Mean SD Mean SD Mean SD Mean SD P *
n 44 38 40 37
Females/males 27/17 28/10 31/9 25/12 0·57
Age (years) 45·0 15·1 41·5 13·6 39·1 10·9 40·3 12·7 0·30
BMI (kg/m2) 24·1 3·0 23·9 2·7 24·5 3·1 24·0 2·8 0·86
Systolic BP (mmHg) 126 15 121 14 119 12 121 13 0·22
Diastolic BP (mmHg) 78·4 10·1 76·2 10·4 76·3 9·6 76·3 9·2 0·71
Total cholesterol (mmol/l) 5·37 0·79 5·03 0·86 4·93 0·78 4·95 0·93 0·18
LDL-cholesterol (mmol/l) 3·33 0·73 2·95 0·70 2·96 0·75 2·98 0·82 0·54
HDL-cholesterol (mmol/l) 1·57 0·45 1·68 0·48 1·56 0·38 1·59 0·35 0·26
TAG (mmol/l) 1·00 0·66 0·84 0·41 0·95 0·54 0·92 0·41 0·38
BP, blood pressure.
* Based on the ANOVA test using means (percentage for sex).

















The increase in plasma EPA varied from 113 to 145 % among
the intervention groups, whereas the increase in DHA varied
from 31 to 50 %. However, differences between the groups
were not significant, indicating that fish oil capsules, enriched
fruit juice and fish paˆte´ represent equivalent sources of dietary
EPA and DHA. The assumption that fish intake is more effec-
tive in increasing plasma levels of EPA and DHA than fish
oil(28,29) was not confirmed in the present study (Table 3).
About 50 % of the intake of EPA and DHA in the fish paˆte´
group originated from fish (salmon) and should therefore
contribute to higher levels in plasma. However, the present
results suggest that incorporation of EPA and DHA into
plasma lipids, measured after 7 weeks of supplementation,
is independent of the food matrix. This is in accordance
with other studies of fortified foods, including foods added
with microencapsulated fish oil(42–48). In the present study,
the incorporation of EPA and DHA into plasma lipids was
somewhat lower, still not significantly lower, in the fruit
juice group than in the fish oil group (Table 3), although
intakes were quite similar (Table 1). As compliance was
Table 3. Fatty acid levels in plasma (mmol/l)
(Mean values and standard deviations)
Baseline Change
n Mean SD Mean SD P * P †
Myristic acid (14 : 0) Fruit juice 38 50·8 28·6 3·6 31·8 0·49
0·59
Fish paˆte´ 44 60·5 36·9 10·0 47·9 0·17
Fish oil 40 67·4 57·1 2·0 44·0 0·77
Control 37 60·5 29·3 22·4 35·5 0·69
Palmitic acid (16 : 0) Fruit juice 38 1667·4 467·5 268·0 288·3 0·15
0·29
Fish paˆte´ 44 1682·5 461·9 7·2 344·2 0·89
Fish oil 40 1661·0 496·5 2139·0 409·5 0·04
Control 37 1652·7 374·2 274·6 322·7 0·18
Palmitoleic acid (16 : 1n-7) Fruit juice 38 69·8 33·6 27·2 27·8 0·12
0·40
Fish paˆte´ 44 64·7 27·1 2·4 24·3 0·52
Fish oil 40 67·7 35·4 24·7 27·9 0·29
Control 37 68·7 33·0 24·8 28·6 0·31
Stearic acid (18 : 0) Fruit juice 38 594·2 143·1 5·2 92·0 0·73
0·15
Fish paˆte´ 44 623·5 147·4 31·9 141·6 0·14
Fish oil 40 580·6 136·6 22·2 133·2 0·92
Control 37 594·8 103·5 232·4 125·4 0·12
Oleic acid (18 : 1n-9) Fruit juice 38 577·6 178·2 248·2 130·4 0·03
0·58
Fish paˆte´ 44 585·8 177·3 22·5 208·3 0·94
Fish oil 40 558·9 166·1 242·7 154·0 0·09
Control 37 570·2 146·8 223·0 151·9 0·36
Linoleic acid (18 : 2n-6) Fruit juice 38 873·9 373·1 272·5 193·5 0·03
0·68
Fish paˆte´ 44 874·0 331·8 227·6 192·0 0·35
Fish oil 40 829·3 349·8 249·6 251·3 0·22
Control 37 812·0 219·6 276·3 167·5 0·01
a-Linolenic acid (18 : 3n-3) Fruit juice 38 62·6 20·4 26·6 19·6 0·05
0·12
Fish paˆte´ 44 65·2 20·5 3·0 22·1 0·37
Fish oil 40 61·7 17·9 0·2 20·9 0·95
Control 37 68·3 20·4 25·5 19·5 0·09
Arachidonic acid (20 : 4n-6) Fruit juice 38 200·1 43·2 218·2 35·5 0·003
0·17
Fish paˆte´ 44 197·7 44·1 23·7 31·4 0·44
Fish oil 40 192·6 50·0 214·1 29·6 0·005
Control 37 189·8 44·2 27·0 32·3 0·20
EPA (20 : 5n-3) Fruit juice 38 30·3 19·9 34·2 29·6 ,0·0001
,0·0001‡
Fish paˆte´ 44 35·5 20·5 51·2 31·5 ,0·0001
Fish oil 40 31·2 23·1 45·2 29·6 ,0·0001
Control 37 43·9 40·7 26·6 28·6 0·17
Docosapentaenoic acid (22 : 5n-3) Fruit juice 38 7·9 3·0 2·7 3·3 ,0·0001
,0·0001‡
Fish paˆte´ 44 9·1 3·5 4·1 4·3 ,0·0001
Fish oil 40 8·8 4·0 3·9 3·2 0·0001
Control 37 9·6 5·1 21·0 3·6 0·09
DHA (22 : 6n-3) Fruit juice 38 46·4 20·0 14·2 19·4 ,0·0001
,0·0001‡
Fish paˆte´ 44 52·0 26·5 19·7 18·5 ,0·0001
Fish oil 40 47·0 25·7 23·4 16·5 ,0·0001
Control 37 57·4 23·7 26·1 21·3 0·09
EPA:AA Fruit juice 38 0·15 0·09 0·20 0·13 ,0·0001
,0·0001‡
Fish paˆte´ 44 0·18 0·09 0·28 0·17 ,0·0001
Fish oil 40 0·16 0·09 0·27 0·17 ,0·0001
Control 37 0·22 0·16 20·02 0·09 0·21
* Test of within-group changes (paired t test).
† Test of the null hypothesis of no difference in change from baseline between the groups (ANOVA).
‡ Mean change from baseline was significantly different for control group than for the other three groups (P,0·05).

















satisfactory in all groups, we have no explanation for the
lower incorporation of EPA and DHA after consumption of
fruit juice and further research is needed to confirm whether
components in fruit juice influence the uptake of fatty acids.
Moreover, it cannot be excluded that small variations in pro-
duct content could have influenced the results. The present
results also show that the increase in plasma EPA is larger
than the increase in plasma DHA in all groups, despite similar
intakes of EPA and DHA (Table 1). This is in accordance with
previous studies(28,29,33,34,45), and may be explained by a more
strict biological regulation of DHA levels.
The increase in plasma EPA and DHA observed in the inter-
vention groups seemed to be paralleled by a decrease in AA
(Table 3), resulting in a marked increase in the EPA:AA ratio.
Elevated blood levels of n-3 LCPUFA and the EPA:AA ratio,
and, in particular, a high percentage of EPA and DHA in eryth-
rocyte membranes (omega-3 index) have been associated with
a reduced risk of sudden cardiac death(1,26,49,50). However,
despite a marked increase in plasma n-3 LCPUFA and the
EPA:AA ratio in the present study, no significant effects were
observed in parameters known to be associated with CVD
such as serum lipids, markers of inflammation and oxidative
stress. Neither did multivariate analyses reveal any strong
associations between the EPA:AA ratio and any of the
measured parameters. The omega-3 index was not measured
in the present study, but future studies should examine
whether n-3 LCPUFA-enriched food products providing
a daily dose of 1 g EPA and DHA is sufficient to achieve the
recommended omega-3 index associated with a reduced risk
of CVD(1,50).
There were no significant effects on serum lipids with the
dose given (1 g/d EPA and DHA), confirming that higher
intakes of 2–4 g/d may be needed to induce significant
reductions in normolipaemic individuals(25,51,52). The
reductions seem to depend on the baseline level and are
more frequently observed in hypertriacylglycerolaemic per-
sons and CVD patients(6,51,53), which may explain why no
change was observed in the present study, which included
only healthy volunteers with normal TAG levels. Some studies
have shown an increase in HDL-cholesterol levels after the
intake of n-3 LCPUFA(51,54). In the present study, only a
weak indication of positive modulation of HDL was observed
(Table 4). The lack of the effects on LDL-cholesterol and
serum cholesterol is as expected, assuming that n-3 LCPUFA
have a minor effect on serum cholesterol(51). The lack of
effect of the intervention products on serum cholesterol
could also be confirmed using serum cholesterol-predictive
equations(55).
The urine levels of F2-isoprostane did not increase signifi-
cantly in any of the study groups (Table 6), indicating no
changes in oxidative stress. The a-tocopherol levels, on the
other hand, tended to decrease from baseline in all groups,
and more in the intervention groups compared with the
control group, but no significant between-group variations
were found. Some studies have shown that intakes of EPA
and DHA may reduce oxidative stress(56), whereas others
have indicated no effect(57), or even increased in vivo lipid
Table 4. Serum lipids (mmol/l)
(Mean values and standard deviations)
Baseline Change
n Mean SD Mean SD P * P †
Total cholesterol Fruit juice 38 5·03 0·86 0·14 0·57 0·14
0·78
Fish paˆte´ 44 5·37 0·79 0·08 0·68 0·47
Fish oil 40 4·93 0·78 0·20 0·42 0·01
Control 37 4·95 0·93 0·12 0·52 0·18
HDL-cholesterol Fruit juice 38 1·68 0·48 0·07 0·23 0·06
0·89
Fish paˆte´ 44 1·57 0·45 0·05 0·17 0·07
Fish oil 40 1·56 0·38 0·05 0·16 0·06
Control 37 1·59 0·35 0·04 0·23 0·29
LDL-cholesterol Fruit juice 38 2·95 0·70 0·03 0·32 0·58
0·35
Fish paˆte´ 44 3·33 0·73 20·03 0·46 0·72
Fish oil 40 2·96 0·75 0·13 0·38 0·04
Control 37 2·98 0·82 0·05 0·36 0·44
TAG Fruit juice 38 0·84 0·41 20·03 0·31 0·50
0·81
Fish paˆte´ 44 1·00 0·66 0·05 0·45 0·46
Fish oil 40 0·95 0·54 20·02 0·46 0·84
Control 37 0·92 0·41 0·02 0·43 0·82
ApoA Fruit juice 38 1·70 0·30 0·07 0·16 0·01
0·71
Fish paˆte´ 43 1·64 0·26 0·04 0·15 0·06
Fish oil 40 1·64 0·27 0·04 0·13 0·06
Control 37 1·68 0·27 0·07 0·17 0·02
ApoB Fruit juice 38 0·79 0·19 20·03 0·12 0·15
0·65
Fish paˆte´ 43 0·90 0·21 20·04 0·14 0·09
Fish oil 40 0·81 0·18 20·01 0·10 0·64
Control 37 0·79 0·20 20·01 0·10 0·41
* Test of within-group changes (paired t test).
† Test of the null hypothesis of no difference in change from baseline between the groups (ANOVA).

















peroxidation and increased oxidative stress(58,59). The conflict-
ing results may be due to differences in experimental design
and different products used. Both dosage and balancing
with appropriate intakes of antioxidants seem to be of major
importance for the outcome.
We have no explanation for the observed increase in inter-
feron-g levels (Table 5). There was no effect on the great
majority of the measured inflammatory markers, and this is
in accordance with a large body of evidence indicating that
healthy subjects are relatively insensitive to immunomodula-
tion with n-3 LCPUFA even at intakes that substantially raise
their concentrations in phospholipids of immune cells(60–64).
A recent study by Micallef et al.(65), however, has indicated
that in healthy individuals, plasma n-3 fatty acid concentration
is inversely related to high-sensitivity C-reactive protein con-
centration. No such correlation was found in the present
study. Moreover, results from the present study are apparently
in contrast to an identically designed previous study where
intake of the same fish paˆte´ resulted in significant decreases
in inflammatory markers (IL-6, TNFa, leukotriene B4 and
monocyte chemotactic protein-1) in lipopolysaccharide-stimu-
lated whole blood(33). The different results may be due to
Table 6. Markers of oxidative stress
(Mean values and standard deviations)
Baseline Change
Study group n Mean SD Mean SD P * P †
Urine F2-isoprostane (mmol/mmol creatinine) Fruit juice 38 0·42 0·29 20·03 0·21 0·31
0·43
Fish paˆte´ 44 0·38 0·30 20·04 0·22 0·28
Fish oil 40 0·38 0·26 0·03 0·19 0·34
Control 37 0·43 0·25 20·02 0·19 0·56
Plasma a-tocopherol (mM/mmol per litre TAG) Fruit juice 38 53·4 30·6 25·56 31·7 0·29
0·87
Fish paˆte´ 44 53·8 33·2 27·92 26·2 0·05
Fish oil 40 49·3 30·2 27·02 28·6 0·13
Control 37 46·4 27·0 22·84 29·2 0·56
* Test of within-group changes (paired t test).
† Test of the null hypothesis of no difference in change from baseline between the groups (ANOVA).
Table 5. Serum high sensitive C-reactive protein (hsCRP) and plasma inflammatory markers
(Mean values and standard deviations)
Baseline Change
Study group n Mean SD Mean SD P * P †
hsCRP (mg/l) Fruit juice 38 1·34 1·69 20·09 1·64 0·72
0·76
Fish paˆte´ 44 1·53 1·81 0·08 2·22 0·81
Fish oil 40 1·28 1·45 0·28 1·62 0·28
Control 37 1·79 2·27 20·18 2·50 0·67
IL-6 (pg/ml) Fruit juice 37 1·38 1·05 0·24 1·38 0·29
0·62
Fish paˆte´ 43 1·96 2·40 0·08 1·51 0·74
Fish oil 34 1·35 0·98 0·23 1·38 0·34
Control 36 1·27 1·05 20·14 1·10 0·44
TNFa (pg/ml) Fruit juice 37 1·91 1·78 20·06 0·69 0·61
0·25
Fish paˆte´ 44 2·01 2·68 0·30 1·07 0·08
Fish oil 35 2·04 3·26 0·03 1·04 0·88
Control 36 1·90 1·41 20·25 1·43 0·30
E-selectin (ng/ml) Fruit juice 38 32·0 11·3 2·0 9·0 0·17
0·97
Fish paˆte´ 42 34·1 13·6 2·3 5·4 0·01
Fish oil 39 32·8 11·8 2·1 7·8 0·11
Control 37 32·4 11·8 1·5 7·0 0·22
ICAM (ng/ml) Fruit juice 38 279·5 69·4 20·5 52·7 0·96
0·57
Fish paˆte´ 42 280·4 68·8 4·2 29·7 0·37
Fish oil 39 299·3 78·5 4·7 36·6 0·44
Control 35 282·3 59·5 26·6 32·3 0·23
MCP-1 (pg/ml) Fruit juice 38 31·7 10·6 0·42 16·0 0·87
0·68
Fish paˆte´ 44 32·2 12·3 2·14 18·8 0·46
Fish oil 40 42·9 75·7 11·0 81·7 0·40
Control 37 32·6 12·4 1·56 16·1 0·56
INFg (pg/ml) Fruit juice 38 168·0 61·23 66·66 125·4 ,0·01
0·16
Fish paˆte´ 44 186·3 93·43 91·01 136·4 ,0·01
Fish oil 40 179·2 80·32 59·27 119·8 ,0·01
Control 37 182·9 132·2 26·66 124·8 0·20
ICAM, intracellular adhesion molecule; MCP-1, monocyte chemotactic protein-1; INFg, interferon-g.
* Test of within-group changes (paired t test).
† Test of the null hypothesis of no difference in change from baseline between the groups (ANOVA).

















healthy subjects generally having low levels of circulating
inflammatory markers, which makes it hard to detect small
changes, whereas with lipopolysaccharide stimulation, much
higher measurable levels of the markers are obtained. The
intervention period in both studies was 7 weeks, which
should ensure sufficient incorporation of n-3 LCPUFA into
the cell membranes(30,34). Incorporation into the membranes
of immune cells may influence their function and the way
they respond to external signals(13,66). Whether lipopolysac-
charide stimulation is relevant with respect to the in vivo situ-
ation needs further investigation and future studies should test
the hypothesis that exposure to pathological conditions, such
as lipopolysaccharide stimulation, is necessary to reveal the
immunomodulatory effects of n-3 LCPUFA associated with
CVD prevention in healthy individuals.
A weakness of the study is that we cannot rule out that
group sizes were too small to detect significant effects on mar-
kers of inflammation and oxidative stress. Another weakness is
that the study was not blinded. The participants received very
different products and this was difficult to hide. In order to
avoid confounding factors such as effects of seasonal variation
and whether participation itself affected the measured par-
ameters, we included a control group that did not consume
any marine n-3 supplements or changed their fatty fish
intake during the study. A nutritionist carefully instructed
them. Also, high baseline n-3 LCPUFA plasma concentrations
could diminish the effects. Regular fatty fish consumers were
therefore not included in the study and all participants were
told to terminate their intake of n-3 LCPUFA supplements 2
months before inclusion(34). Hence, baseline values were
somewhat lower in the present study. Still, plasma n-3
LCPUFA calculated as a percentage of total fatty acids were
similar to other studies and the observed increases in n-3
LCPUFA were within the same range as observed by
others(28,33,67,68).
In conclusion, the present study shows that concentrated
fish oil in capsules, enriched fruit juice and fish paˆte´ represent
suitable delivery systems for EPA and DHA, i.e. the efficiency
of the incorporation into plasma lipids was independent of the
food matrix. Fruit juice and fish paˆte´ were safe, well tolerated
and highly palatable, representing feasible alternatives to meet
the nutritional recommendations. Fruit juice can be advised
for individuals who do not favour fish or fish oil capsules.
The products effectively increase plasma n-3 LCPUFA content
and the EPA:AA ratio. However, significant effects on serum
lipids and markers of inflammation and oxidative stress were
not observed in this healthy population.
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